DIAGNOSIS AND MANAGEMENT OF DYSLIPIDEMIA
TABLE OF CONTENTS
|
Introduction |
10 |
|
|
|
|
Nomogram to convert plasma cholesterol values from mg/dl to mmol/L |
12 |
|
Nomogram to convert plasma triglycerides values from mg/dl to mmol/L |
13 |
|
|
|
|
Chapter I. Cholesterol and lipoproteins |
14 |
|
Major steps of cholesterol biosynthesis |
15 |
|
Classification of plasma lipoproteins |
16 |
|
General structure of lipoproteins |
18 |
|
Structure of low-density lipoproteins (LDL) |
19 |
|
Lipoprotein pathways: exogenous |
20 |
|
Lipoprotein lipase and triglyceride-rich lipoproteins |
21 |
|
Lipoprotein pathways: endogenous |
22 |
|
|
|
|
Chapter II. Cholesterol, lipoproteins and atherosclerosis |
24 |
|
Natural history of atherosclerotic disease |
28 |
|
Gross morphology of atherosclerotic lesions |
29 |
|
Nomenclature and sequence of atherosclerotic lesions |
30 |
|
Plaque structure |
32 |
|
Pathophysiological role of plaque rupture |
35 |
|
Histologic section of a thrombosed coronary artery |
37 |
|
Angiographic picture of a thrombosed coronary artery |
38 |
|
Endothelial injury resulting in coronary thrombosis |
39 |
|
|
|
|
Chapter III. Plasma lipoprotein analysis |
40 |
|
Factors influencing plasma lipoprotein level |
41 |
|
Classification based on total cholesterol and high density lipoprotein (HDL)-cholesterol |
42 |
|
Risk factors for coronary artery disease (CAD) |
43 |
|
Primary CAD prevention in adults based on total cholesterol and HDL-cholesterol |
45 |
|
Clinical importance of LDL measurement |
46 |
|
Classification based on LDL-cholesterol |
47 |
|
Primary CAD prevention in adults based on LDL-cholesterol |
48 |
|
Secondary CAD prevention in adults based on LDL-cholesterol |
49 |
|
Classification of triglyceride plasma levels |
50 |
|
Therapeutic classification of hyperlipidemia |
51 |
|
Selected causes of secondary hyperlipidemia |
52 |
|
|
|
|
Chapter IV. Management of hyperlipidemia |
53 |
|
When to initiate dietary therapy? |
56 |
|
Dietary theory of high blood cholesterol |
57 |
|
General considerations regarding lipid-lowering diet |
58 |
|
Desirable body weight |
61 |
|
When to prescribe lipid-lowering drugs? |
62 |
|
Lipid-lowering agents |
63 |
|
Bile acid sequestrants |
64 |
|
Nicotinic acid |
66 |
|
HMG-CoA reductase inhibitors (statins) |
69 |
|
Fibrates |
72 |
|
Probucol |
74 |
|
Combination therapy of dyslipidemia |
76 |
|
Drug selection in dyslipidemia |
77 |
|
|
|
|
Chapter V. Efficacy of lipid-lowering therapy |
78 |
|
West of Scotland Study |
80 |
|
4S |
82 |
|
CCAIT |
84 |
|
PLAC I |
86 |
|
REGRESS |
88 |
|
ACAPS |
90 |
|
PLAC II |
92 |
|
|
|
|
Clinical macroresults of angiographic microchanges (instead of afterward) |
94 |
|
|
|
|
Bibliography |
96 |
|
|
|
|
List of slides |
104 |
© V. Kryzhanivsky, 1995